Kornimate/medical-research-clean huggingface dataset:
cohort follow-up of epidemic and neuroimaging for patients during the 1st wave of the covid-19 in china

Conditions: COVID-19; Post-COVID-19 Syndrome; Acute COVID-19; Post-Acute COVID-19

Summary: our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the covid-19. besides, we aim to establish a database of post-covid-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long covid and prevent the neurological symptoms evolution, optimize the tactics of management in china.

this is an observational, cross-sectional, and multicenter study. it will be performed at 9 public hospitals. participants with confirmed cases of mild or moderate covid-19 infection will complete the following programs at acute infection phase and after 3, 12 months for exploring biological mechanism and predictive biomarkers of post-covid-19: 1) fill in the behavioral psychology scales, 2) submit blood samples at a local laboratory, 3) accept the simultaneous cortico-spinal magnetic resonance imaging scan. the uninfected healthy controls will complete the same programs as infected group mentioned above only at the time of inclusion. we will establish the simultaneous cortico-spinal magnetic resonance imaging database containing neuropsychological scales and blood parameters of post-covid-19 in china.

Eligibility criteria:
inclusion criteria: confirmed diagnosis of mild covid-19 (who criteria)/confirmed diagnosis of moderate covid-19 (who criteria)/healthy people who have not had covid-19 exclusion criteria: history of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. participants with indication for mri studies

Keywords: covid-19 post-covid-19 syndrome neuroimaging epidemic simultaneous cortico-spinal magnetic resonance imaging
the effect of cocoa flavanol on the bold response and cognitive function in type 1 diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: type 1 diabetes (t1d) is associated with microvascular changes in the brain, which can cause cognitive dysfunction. cocoa flavanols (cf) can stimulate vasodilation, resulting in enhanced cerebral blood flow and better cognitive function. this study aimed to investigate whether acute cf supplementation can improve cognitive function and the hemodynamic (bold) response in t1d patients.


Eligibility criteria:
inclusion criteria: * non-smoking t1d patients or matched healthy controls * having diabetes for more than 1 year * males and females older than 18 years * stable medications for more than 6 months (no use of cholinesterase inhibitors or prior use of multivitamins was allowed) * adequate visual and auditory acuity to allow neuropsychological testing. exclusion criteria: * participant enrolled in any investigational drug study within 2 months or longer, depending on the investigational drug half-life * history in the past 2 years of epileptic seizures or any major psychiatric disorder * history or mri evidence of brain damage, including significant trauma, stroke, hydrocephalus, mental retardation, or serious neurological disorder, * significant history of alcoholism or drug abuse * unstable cardiac, renal, lung, liver, or other severe chronic disease * hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pres-sure ≥100 mmhg) or hypotension (systolic blood pressure \<100 mmhg) * pacemaker or other medical metal devices that precludes performing mri, * chronic inflammatory diseases, including lupus, rheumatoid arthritis, or polymyalgia rheumatic * macrovascular complications * retinopathy, nephropathy or neuropathy (microvascular complications)
use of a radiopaque localizer grid and methylene blue staining as an aid to reduce radiation exposure

Conditions: Bone Diseases

Summary: localization of small femur lesions for resection can be challenging and may be associated with the need for significant fluoroscopic imaging and tissue dissection.

this study was performed to evaluate the use of a radiopaque localizer grid along with methylene blue staining for resection of small femur lesions in children, and to determine this technique's effectiveness at reducing radiation exposure and tissue injury.

Eligibility criteria:
inclusion criteria: * patients with lesions \<20.0 mm exclusion criteria: * patients with lesions \>20.0 mm

Keywords: radiopaque localizer grid methylene blue reduce radiation exposure
the hip fracture surgical approach trial

Conditions: Hip Fracture; Femoral Neck Fracture

Summary: the hifsat study will compare the standard direct lateral approach to hemiarthroplasty to a new muscle sparing approach (spaire) in femoral neck fracture patients.

femoral neck fractures are mostly treated with a hemiarthroplasty, where the fractured femoral head is replaced with a metal implant. the most common surgical approach to hemiarthroplasty has been the lateral approach, in which the gluteus medius tendon is partially released from the greater trochanter. hip pain and limping is not uncommon after this approach has been used. a new surgical approach (spaire) has been developed to alleviate this problem, and in this method the surgeon approaches the injured hip joint from posterior, preserving most of the muscles and tendons around the hip. this trial is designed to assess if this new spaire approach leads to better results than the lateral approach in patients with femoral neck fractures.

Eligibility criteria:
inclusion criteria: * femoral neck fracture * clinical indication for hemiarthroplasty * age over 50 years exclusion criteria: * previous hip implants in the same hip * patients assessed to be in a terminal state with an expected survival of less than 1 week * other factors that makes follow-up impossible

Keywords: fragility fracture surgical approach hemiarthroplasty spaire direct lateral approach hip surgery
atracurium mixed with magnesium sulfate versus atracurium alone as adjuvant to lidocaine in ivra

Conditions: Postoperative Pain

Summary: the present clinical study will be undertaken to compare study between the effect of atracurium with lidocaine versus addition of magnesium sulphate to the same doses with lidocaine administrated alone in intravenous regional anaesthesia to access motor block, sensory block, tourniquet pain and post operative analgesia .also assessment of patient and surgeon satisfaction .

patients will be divided randomly into three groups (a, b, c) of 25 each, according to computer generated table of random numbers. * patients in group a will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml. * patients in group b receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml. * patients in group c will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml. onset of sensory block will be assessed by a pin prick performed at 1 minute interval in the dermatomal sensory distribution of the medial and lateral ante brachial cutaneous, ulnar, median and radial nerves. sensory block onset time will be recorded as time elapsed from injection of drug to sensory block achieved in all dermatomes.onset of motor block will be assessed by asking the subject to flex and extend his/her wrist and fingers. monitoring of motor block will be assessed by modified bromage score . complete motor block will be recorded when no voluntary movement will be possible. at the end of surgery, the tourniquet will be deflated by a cyclic deflation technique and recording this : * sensory block recovery time * motor block recovery time * mean arterial pressure (map), * heart rate (hr) * visual analogue scale (vas) will be recorded at 0, 15 min , 1, 6, 12, and 24 h. * the time to first analgesic requirement will be recorded (the time elapsed from tourniquet release until first patient request for analgesic). patient and surgeon satisfaction

Eligibility criteria:
inclusion criteria: * short procedures (less than 2 hours). * cooperative patients. exclusion criteria: * patients with sickle cell anemia. * history of drug allergy. * raynaud's disease. * scleroderma. * myasthenia gravis. * cardiac disease. * diabetes mellitus. * peptic ulcer. * gastritis. * liver or renal insufficiency. * patients with history of convulsions .
alf-one : alfuzosin once daily

Conditions: Prostatic Hyperplasia

Summary: the aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (luts) suggestive of benign prostatic hyperplasia (bph).


Eligibility criteria:
inclusion criteria: * ambulatory patients suffering from lower urinary tract symptoms suggestive of benign prostatic hyperplasia exclusion criteria: * patients requiring benign prostatic hyperplasia surgery immediately or within the 12 following months * patients previously not improved by an alpha 1-blocker treatment * patients whose urinary symptoms are satisfactorily controlled on other benign prostatic hyperplasia medication (alpha 1-blockers and 5-ari) * known hypersensitivity to alfuzosin * history of postural hypotension or syncope * combination with other alpha 1-blockers * hepatic insufficiency * unstable angina pectoris * severe concomitant condition threatening life
the school spit study - elementary schools in low covid-19 incidence regions

Conditions: SARS-CoV2 Infection

Summary: this study will conduct an evaluation of a program that is being implemented sickkids / toronto public health that provides take-home saliva testing kits in schools. operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. this study will leverage this chance implementation to do a robust evaluation of the public health intervention. schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center, primary care or acute care facility) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. the investigators will evaluate the impact of the program on sars-cov-2 case identification in schools.

this is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design. eligible elementary public schools toronto region in low sars-cov-2 incidence regions (quintiles 1,2 or 3) will be randomized. the study will occur over a 7-week period with a minimum of one-week of baseline data (control phase - testing at an assessment center, primary care or acute care center) and then schools will start the program in a stepwise manner (20 crossovers per week) with take-home saliva being available to all 120 schools by the end of the study period. the primary objective of the study is to assess whether the availability of take home saliva kits at schools for symptomatic testing leads to increased diagnosis of sars-cov-2 cases in the school.

Eligibility criteria:
elementary schools will be included in the evaluation if they are: * considered an elementary school by the school board * open for in-person learning during the study period * they have at least 200 students * offer at least 4 grades exclusion criteria: schools that are middle schools only, that are not open for in-person learning, have fewer than 200 students or are not a complete elementary school (i.e.schools offering independent courses, prep schools with 1-2 grades, elementary schools with \< 4 grades) will be excluded.

Keywords: school testing
primary tbe vaccination for the elderly

Conditions: Tick-borne Encephalitis; Vaccine

Summary: tick-borne encephalitis (tbe) can be prevented by vaccine. vaccine failure, defined as a case of tbe regardless of previous vaccination, has been described and seems to be more predominant with increasing age, suggesting a less effective immune response following with increasing age. in fact previous studies has shown a reduced antibody response in elderly individuals compared to younger when vaccinated against tbe. as a result, in sweden, an extra vaccine dose has been recommended during the primary vaccine schedule to individuals \> 50 years of age. this alternative vaccine schedule has not been tested. the investigator aim to test if an extra vaccine dose in the primary vaccine schedule for those \> 50 years of age improves the immune response and offers a corresponding immunity to younger individuals following tbe vaccination.


Eligibility criteria:
inclusion criteria: * adults ≥ 50 years or between 18-40 years * man or woman * god health * written informed consent exclusion criteria: * previous vaccination against tbe * previous tbe infection * allergy or hypersensitivity to any substance in the vaccine * previously known or suspected infection with japanese encephalitis, dengue virus, west nile fever or yellow fever * information on previous vaccination against yellow fever or japanese encephalitis * acute illness, eg fever with malaise * immunosuppression, due to medication or disease * previous treatment with rituximab or equivalent * autoimmune disease, including diabetes (diet or tablet-treated diabetes with good metabolic control is accepted, hba1c \< 6 %) * obesity, bmi \> 40 * moderate to severe renal failure including hemodialysis, estimated gfr \< 30. * blood transfusion or immunoglobulins \<3 months ago * pregnancy * any other illness where the investigator consider the subject unsuitable for the study * the study subject does not want to participate

Keywords: elderly tick-borne encephalitis vaccine
inflammation genomics and atherosclerosis - ancillary to cardia

Conditions: Cardiovascular Diseases; Atherosclerosis; Coronary Arteriosclerosis; Inflammation; Heart Diseases; Thrombosis

Summary: to examine the associations of common variation in inflammation/thrombosis genes with intermediate quantitative phenotypes and subclinical coronary atherosclerosis in the coronary artery risk factor development in young adults (cardia) study, a large, bi-racial cohort study.

background: atherosclerosis is a major determinant of coronary heart disease and is determined by the interplay of genetic and environmental risk factors. although atherosclerosis tends to aggregate in families, it does not exhibit classical mendelian segregation. thus, the genes that determine an individual's risk of atherosclerosis likely involve multiple sites within genes and interactions between genes, all of which define a genetic risk that is modified by the host environment. design narrative: the genetic epidemiology study examines the associations of common variation in inflammation/thrombosis genes with intermediate quantitative phenotypes and subclinical coronary atherosclerosis in the coronary artery risk factor development in young adults (cardia) study, a large, bi-racial cohort study. the set of 25 candidate genes involve pathways (cytokines, chemokines, and their receptors; cellular adhesion molecules; and, coagulation proteins) and include several receptor-ligand pairs. using cladistic analysis and the resources of the program in genomic applications (pga), the investigators will identify a limited set of single nucleotide polymorphisms (range 3-10 snps per gene) that characterize common haplotypes in these candidate genes within persons of african descent and european descent. dna from the cardia year 10 examination (n = 3,950 subjects) will be genotyped for the selected variants that characterize the common haplotypes. data on the presence of common variants and haplotypes will be incorporated into the cardia study database. levels of two important intermediate phenotypes, fibrinogen and c-reactive protein (crp) were previously determined. non-invasive assessment of coronary atherosclerosis, defined as the presence of coronary artery calcification (cac), was obtained on cardia participants at the year 15 exam. analyses will be stratified by race/ethnicity and focus on the associations of the common haplotypes with fibrinogen, crp, and cac measured in early adult life. secondarily, the investigators will explore possible gene-gene and gene-environment interactions. the proposed multi-disciplinary collaboration should enhance the sensitivity and specificity of efforts to assess the associations of common variation in sets of inflammation/thrombosis candidate genes and cardiovascular risk in young adults.

Eligibility criteria:
cardiac cohort participants with dna
pilot clinical trial to evaluate the uni-deb for unresectable hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: pilot clinical trial to evaluate the efficacy and safety of uni-deb for unresectable hepatocellular carcinoma


Eligibility criteria:
inclusion criteria: * over 19 years * diagnosis of hcc * unresectable asymtomatic uninodular or multinodular tumor. * subject who maintain clinically normal hepatopetal flow without main portal vein closure * at least one measurable target lesion by ct or mri which 10 mm or more. * ecog performance status of 0 or 1. * child-pugh class a or b * life expectancy of at least 6 months. exclusion criteria: * another primary tumour, with the exception of conventional basal cell carcinoma or superficial bladder neoplasia * hepatic resection, liver transplantation or percutaneous local treatment * previously received hcc related medical procedure * previously treated with anthracyclines * only measurable disease is within an area of the liver previously subjected to radiotherapy. * child pugh c * active gastrointestinal bleeding within 6 months from screening. * total bilirubin \> 3mg/dl * wbc \< 3,000cells/mm3 * anc \< 1,500cells/mm3 * platelet \< 50,000mm3 * serum creatinine \> 2mg/dl * inr \> 1.4 * alt and ast \> 5 times unl * diffuse hcc defined as \>50% tumor involvement of the whole liver.
treatment resistance related with gene expression profile of diffuse large b-cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: the investigators perform a retrospective microarray gene expression profiling study of ffpe from a cohort of dlbcl patients with whole genome cdna mediated annealing selection and ligation (wg-dasl) assay. the investigators also study the pattern of microrna from patients with diffuse large b-cell lymphoma. the results of gene expression profiles and microrna is correlated with clinical outcomes of diffuse large b-cell lymphoma.

1. whole genome cdna mediated annealing selection and ligation (wg-dasl) assay * diffuse large b-cell lymphoma patients * paraffin-embedded tissue * end points: progression-free survival, overall survival * statistics: leave one-out method 2. nano string assay for microrna * diffuse large b-cell lymphoma patients * paraffin-embedded tissue * end points: progression-free survival, overall survival * statistics: leave one-out method

Eligibility criteria:
inclusion criteria: * patients diagnosed with diffuse large b-cell lymphoma * patients with tissue blocks available for study * patients with adequate medical records exclusion criteria: * patients diagnosed with other subtypes of lymphoma

Keywords: lymphoma prognosis relapse gene microrna
the effect of posterior pericardiotomy on the incidence of atrial fibrillation after cardiac surgery

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to determine if preforming a posterior left pericardiotomy prevents atrial fibrillation after cardiac surgery.

post-operative atrial fibrillation (poaf) is a common complication of cardiac surgery which is observed in 30-40% of patients. poaf may cause stroke, systemic embolism or cardiac failure and its detection mandates for additional treatment with variable combinations of drugs to control cardiac rate or rhythm, anticoagulation, and electrical cardioversion, with their side effects and complications. as a result, poaf prolongs hospital stay and increases the costs of hospitalization. several strategies aimed at reducing the incidence of poaf have been investigated, including beta-blockers, amiodarone, and statins, with unsatisfactory results. posterior left pericardiotomy has been associated with a reduction in the incidence of poaf in a few studies. however, these studies are flawed by methodological limitations in terms of sample size, inclusion/exclusion criteria, randomization procedure, and suboptimal electrocardiographic monitoring strategies. moreover, posterior left pericardiotomy requires additional operative time and is associated with procedure-specific complications. as a result, current evidence on posterior pericardiectomy failed to translate into changes in clinical practice and the incidence of poaf remains high.

Eligibility criteria:
inclusion criteria: * all consecutive patients admitted to the department of cardiothoracic surgery of the nyph-wcmc will be screened for enrollment. exclusion criteria: * preoperative non-sinus rhythm * history of previous atrial arrhythmia of any type * reoperations * mitral or tricuspid valve disease * surgery of the descending thoracic or thoracoabdominal aorta * need for hypothermic circulatory arrest * off pump operation * urgent/emergent presentation * disease of the left pleura or previous left thoracotomy * chest deformity

Keywords: postoperative pericardiotomy prevention cardiac surgery left posterior
effectiveness of a nutraceutical in raising circulating serum vitamin, mineral and amino acid levels in patients.

Conditions: Vitamin Deficiency

Summary: the purpose of this study is to correlate the findings of an early study with current data.


Eligibility criteria:
inclusion criteria: healthy volunteers whose circulating serum vitamin a1, e, b1,b2,b6,b12,c,d, calcium, iron, igf-1 and ft-3 are within normal limits. a1; 48-85 ug/dl, e; 5.3-17.5 mg/l, b1; 66.5-200 nmo/l, b2; 137-370 ug/l, b6; 2-32.8 ug/l, b12; 211-946 pg/ml, c; 0.2-2.0 mg/dl, d; 30-100 ng/ml, calcium; 8.7-10.2 mg/dl, iron; 27-159 ug/dl, igf-1; 67-205 ng/ml, ft-3; 2-4.4 pg/ml exclusion criteria: volunteers whose circulating serum vitamin a1, e, b1,b2,b6,b12,c,d, calcium, iron, igf and ft-3 are outside normal limits. a1; 48-85 ug/dl, e; 5.3-17.5 mg/l, b1; 66.5-200 nmo/l, b2; 137-370 ug/l, b6; 2-32.8 ug/l, b12; 211-946 pg/ml, c; 0.2-2.0 mg/dl, d; 30-100 ng/ml, calcium; 8.7-10.2 mg/dl, iron; 27-159 ug/dl, igf-1; 67-205 ng/ml, ft-3; 2-4.4 pg/ml -